The use of a modified [3H]4-DAMP radioligand binding assay with increased selectivity for muscarinic M3 receptor shows that cortical CHRM3 levels are not altered in mood disorders

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 47, Issue , 2013, Pages 7-12

  Jeon, Won Je ^a,b   Gibbons, Andrew S ^a,b   Dean, Brian ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

3H 4 DAMP; Bipolar disorder; Major depressive disorder; Muscarinic receptors; Radioligand binding

Indexed keywords

4 DIPHENYLACETOXY 1 METHYLPIPERIDINE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M4 RECEPTOR; 4 DIPHENYLACETOXY 1,1 DIMETHYLPIPERIDINIUM; 4-DIPHENYLACETOXY-1,1-DIMETHYLPIPERIDINIUM; CHRM1 PROTEIN, HUMAN; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PIPERIDINE DERIVATIVE; PIRENZEPINE; TRITIUM;

ADULT; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIPOLAR DISORDER; BRAIN CORTEX; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; KNOCKOUT MOUSE; LIGAND BINDING; MAJOR DEPRESSION; MALE; MOOD DISORDER; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECEPTOR BINDING; WESTERN BLOTTING; WILD TYPE; 4-DAMP; 4-DIPHENYLACETOXY-N-METHYLPIPERIDINE; [(3)H]4-DAMP; AGED; ANIMAL; BPD; CHRM; CON; DOSE RESPONSE; DRUG EFFECT; ESTIMATED TISSUE EQUIVALENT; ETE; GENETICS; HEALTHY CONTROL; IC; INTERNAL CONTROL; MDD; METABOLISM; MIDDLE AGED; MUSCARINIC RECEPTORS; PATHOLOGY; PROTEIN BINDING; RADIOASSAY; RADIOLIGAND BINDING; SCINTISCANNING;

4-DAMP; 4-DIPHENYLACETOXY-N-METHYLPIPERIDINE; [(3)H]4-DAMP; BIPOLAR DISORDER; BPD; CHOLINERGIC MUSCARINIC RECEPTOR; CHRM; CON; ESTIMATED TISSUE EQUIVALENT; ETE; HEALTHY CONTROL; IC; INTERNAL CONTROL; MAJOR DEPRESSIVE DISORDER; MDD; MUSCARINIC RECEPTORS; RADIOLIGAND BINDING;

ADULT; AGED; ANIMALS; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MICE, KNOCKOUT; MIDDLE AGED; MOOD DISORDERS; MUSCARINIC ANTAGONISTS; PIPERIDINES; PIRENZEPINE; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M3; RECEPTORS, MUSCARINIC; TRITIUM;

EID: 84883325149     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2013.08.001     Document Type: Article

References (34)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington, DC. 4th ed.
2. 3H]4-DAMP to muscarinic cholinergic sites in the rat brain: evidence from membrane binding and autoradiographic studies. Synapse 1991, 9:165-176.
3. Buckley N.J., Bonner T.I., Brann M.R. Localization of a family of muscarinic receptor messenger-RNAs in rat-brain. J Neurosci 1988, 8:4646-4652.
4. Cannon D.M., Carson R.E., Nugent A.C., Eckelman W.C., Kiesewetter D.O., Williams J., et al. Reduced muscarinic type 2 receptor binding in subjects with bipolar disorder. Arch Gen Psychiatry 2006, 63:741-747.
5. Cannon D.M., Klaver J.K., Gandhi S.K., Solorio G., Peck S.A., Erickson K., et al. Genetic variation in cholinergic muscarinic-2 receptor gene modulates M-2 receptor binding in vivo and accounts for reduced binding in bipolar disorder. Mol Psychiatry 2011, 16:407-418.
6. Comings D.E., Wu S., Rostamkhani M., McGue M., Iacono W.G., MacMurray J.P. Association of the muscarinic cholinergic 2 receptor (CHRM2) gene with major depression in women. Am J Med Genet 2002, 114:527-529.
7. Crook J.M. A possible role for muscarinic cholinergic receptors in the pathology and treatment of schizophrenia 1998, University of Melbourne.
8. Crook J.M., Dean B., Pavey G., Copolov D. The binding of H-3 AF-DX 384 is reduced in the Caudate-Putamen of subjects with schizophrenia. Life Sci 1999, 64:1761-1771.
9. Crook J.M., Tomaskovic-Crook E., Copolov D.L., Dean B. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 2001, 158:918-925.
10. Dean B., Pavey G., McLeod M., Opeskin K., Keks N., Copolov D. A change in the density of [H-3]flumazenil, but not [H-3]muscimol binding, in Brodmann's Area 9 from subjects with bipolar disorder. J Affect Disord 2001, 66:147-158.
11. Dean B., Soulby A., Evin G.M., Scarr E. Levels of [H-3]pirenzepine binding in Brodmann's area 6 from subjects with schizophrenia is not associated with changes in the transcription factor SP1 or BACE1. Schizophr Res 2008, 106:229-236.
12. Dean B., Gibbons A.S., Tawadros N., Brooks L., Everall I.P., Scarr E. Different changes in cortical tumor necrosis factor-[alpha]-related pathways in schizophrenia and mood disorders. Mol Psychiatry 2013, 18:767-773.
13. Egan R.M. Muscarinic receptors. Handbook of experimental pharmacology 2012, 3-28. Springer, Germany. A.D. Fryer, A. Christopoulos, N.M. Nathanson (Eds.).
14. Gibbons A.S., Scarr E., McOmish C.E., Hannan A.J., Thomas E.A., Dean B. Regulator of G-protein signalling 4 expression is not altered in the prefrontal cortex in schizophrenia. Aust N Z J Psychiatry 2008, 42:740-745.
15. Gibbons A.S., Scarr E., McLean C., Sundram S., Dean B. Decreased muscarinic receptor binding in the frontal cortex of bipolar disorder and major depressive disorder subjects. J Affect Disord 2009, 116:184-191.
16. Gibbons A.S., Scarr E., Boer S., Money T., Jeon W.J., Felder C., et al. Widespread decreases in cortical muscarinic receptors in a subset of people with schizophrenia. Int J Neuropsychopharmacol 2012, 1-10.
17. Gliner J.A., Morgan G.A., Harmon R.J. Basic associated designs: analysis and interpretation. J Am Acad Child Adolesc Psychiatry 2002, 41:1256-1258.
18. Keks N., Hill C., Opeskin K., Copolov D.L., Dean B. Psychiatric diagnosis after death: the problems of accurate diagnosis. Using CNS tissue in psychiatry research: a practical guide 1999, 19-37. J. Gordon & Breach Science Publishers, Sydney. B. Dean, T.M. Hyde, J.E. Klienman (Eds.).
19. Levey A.I. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993, 52:441-448.
20. Levey A.I., Edmunds S.M., Heilman C.J., Desmond T.J., Frey K.A. Localization of muscarinic M3 receptor protein and M3 receptor-binding in rat-brain. Neuroscience 1994, 63:207-221.
21. Michel A.D., Stefanich E., Whiting R.L. Direct labeling of rat M3-muscarinic receptors by H-3 4damp. Eur J Pharmacol 1989, 166:459-466.
22. Oki T., Takagi Y., Inagaki S., Taketo M.M., Manabe T., Matsui M., et al. Quantitative analysis of binding parameters of [3H]N-methylscopolamine in central nervous system of muscarinic acetylcholine receptor knockout mice. Brain Res Mol Brain Res 2005, 133:6-11.
23. Pinter I., Moszkovszkin G., Nemethy Z., Makara G.B. Muscarinic M-1 and M-3 receptors are present and increase intracellular calcium in adult rat anterior pituitary gland. Brain Res Bull 1999, 48:449-456.
24. Pralong D., Tomaskovic-Crook E., Opeskin K., Copolov D., Dean B. Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia. Schizophr Res 2000, 44:35-45.
25. Raedler T.J., Knable M.B., Jones D.W., Urbina R.A., Gorey J.G., Lee K.S., et al. In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 2003, 160:118-127.
26. Scarr E., Dean B. Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?. J Neurochem 2008, 107:1188-1195.
27. Tsang S.W.Y., Francis P.T., Esiri M.M., Wong P.T.H., Chen C., Lai M.K.P. Loss of H-3 4-DAMP binding to muscarinic receptors in the orbitofrontal cortex of Alzheimer's disease patients with psychosis. Psychopharmacology (Berl) 2008, 198:251-259.
28. Vanwaarde A., Visser G.M., Visser T.J., Bouwer J., Paans A.M., Vaalburg W. Rodent biodistribution and metabolism of tritiated 4-DAMP, a M(3) subtype-selective cholinoceptor ligand. Nucl Med Biol 1994, 21:41-47.
29. Vilaro M.T., Palacios J.M., Mengod G. Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry. Neurosci Lett 1990, 114:154-159.
30. Wei J., Walton E.A., Milici A., Buccafusco J.J. m1-m5 muscarinic receptor distribution in rat CNS by RT-PCR and HPLC. J Neurochem 1994, 63:815-821.
31. Yamamoto N., Yoshida A., Taki Y., Onoue S., Kagawa Y., Yamada S. Up-regulation of nicotinic and muscarinic receptor mRNA in rat bladder by repeated administration of nicotine in relation to the pharmacokinetics. Life Sci 2011, 89:343-348.
32. Yasuda R.P., Ciesla W., Flores L.R., Wall S.J., Li M., Satkus S.A., et al. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol Pharmacol 1993, 43:149-157.
33. Zavitsanou K., Katsifis A., Mattner F., Huang X.-F. Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 2004, 29:619-625.
34. Zubieta J.K., Frey K.A. Autoradiographic mapping of M3-muscarinic-receptors in the rat-brain. J Pharmacol Exp Ther 1993, 264:415-422.